MediWound’s EscharEx Featured in Paper as a Potential Paradigm Shift Towards Non-Surgical Wound Bed Preparation in DFUs
Retrieved on:
Wednesday, November 9, 2022
Diabetes, GLOBE, Review, Phrase, Enzyme, Calendar, DFU, Form 20-F, Food, Regeneration, Research, Annual report, Podiatry, Ulcer, Debridement, Mouth ulcer, Development, Bromelain (pharmacology), COVID-19, BARDA, Hospital, Wound healing, European, NASDAQ, Safety, Survival, Burn, PDUFA, Contract, Company, Government, VLU, European Medicines Agency, Patient, Growth, FDA, Pharmaceutical industry, Medical device
YAVNE, Israel, Nov. 09, 2022 (GLOBE NEWSWIRE) -- MediWound Ltd. (NASDAQ: MDWD), a fully integrated biopharmaceutical company focused on next-generation biotherapeutic solutions for tissue repair and regeneration, today announced the publication of a paper, “Introducing Bromelain-Based Enzymatic Debridement” in the journal Podiatry Management. The paper reviewed past studies and summarized physicians’ experiences in using EscharEx® for the debridement and wound bed preparation of Diabetic Foot Ulcers (DFUs).
Key Points:
- The paper reviewed past studies and summarized physicians experiences in using EscharEx for the debridement and wound bed preparation of Diabetic Foot Ulcers (DFUs).
- EscharEx, MediWounds next generation topical debridement agent is a complex mixture of proteolytic enzymes enriched in bromelain developed for the treatment of chronic and other hard-to-heal wounds.
- This represents a potential paradigm shift from surgical debridement to a fast, effective, safe, practical and user-friendly treatment of chronic and hard to heal wounds.
- We were pleased to see that the physicians experiences highlighted in this paper are similar to the results in our other EscharEx clinical trials, said Dr.